This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Acute schizophrenia-like psychotic disorder급성 조현병-유사정신병장애 (급성조현병유사정신병)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: F23.2 (Acute schizophrenia-like psychotic disorder) | Special Copayment Reduction: V161 (severe intractable disease, 5 years)
B. SynonymsAcute undifferentiated schizophrenia, brief schizophreniform disorder, brief schizophreniform psychosis, oneirophrenia, schizophrenic reaction
C. Adult onsetPossibility of first presenting in adulthood Very high — overlaps with the age range of onset of schizophrenia (18 to 30s), and differentiation from the first episode of schizophrenia is the main clinical task; the F23.2 diagnosis is maintained if complete recovery occurs within 1 month.
1. HistoryDerived from Langfeldt's (1939) concept of schizophreniform psychosis; established as a separate diagnosis, schizophreniform disorder, in DSM-III (1980); classified as F23.2 in ICD-10.
2. CausesGenetic vulnerability shared with schizophrenia, dopamine and glutamate abnormalities; acute stress triggers symptoms meeting schizophrenia criteria in vulnerable individuals but with short-term recovery; exclusion of organic causes is essential.
3. GeneticsHigh genetic overlap with schizophrenia; schizophrenia PRS scores tend to be elevated in F23.2 patients as well; risk of conversion to schizophrenia after the first episode about 30-50%.
4. General epidemiologyIncidence about 1/10 that of schizophrenia; onset in early adulthood; in DSM schizophreniform disorder epidemiologic data, annual incidence about 1-2 per 100,000 population; conversion rate to schizophrenia about 30-50%.
5. PathophysiologySame mechanism as the neurobiology of schizophrenia (dopamine hypersensitivity, NMDA hypofunction, prefrontal-limbic abnormalities); the key difference is preserved neuroplasticity or resolution of stress, which allows short-term recovery.
6. SymptomsMeets schizophrenia diagnostic criterion A (2 or more of hallucinations, delusions, disorganized speech, disorganized behavior, negative symptoms); duration less than 1 month (ICD) or 1-6 months (DSM schizophreniform); no mood episode.
7. SignsSame positive symptom findings as schizophrenia (auditory hallucinations, delusions, disorganized speech); negative symptoms mild or absent; premorbid functioning is often better than in schizophrenia.
8. ScreeningSame immediate evaluation as for a first episode of schizophrenia; complete exclusion of organic causes (including autoimmune encephalitis); concurrent use of early psychosis clinical high-risk assessment tools.
9. DiagnosisICD-10 F23.2: meets schizophrenia criterion A + duration less than 1 month; DSM-5 schizophreniform disorder: meets schizophrenia criterion A + 1-6 months; reclassified as F20 if exceeding 1 month.
10. TreatmentActive antipsychotic treatment; linkage to early psychosis program; maintenance treatment duration of 12-24 months recommended (considering risk of conversion to schizophrenia); combined cognitive behavioral therapy and family education.
11. PrognosisGood short-term prognosis (recovery possible within 1 month); long-term prognosis uncertain because of risk of conversion to schizophrenia; conversion risk about 30-50%; conversion may be preventable by early intervention.
12. PreventionEarly psychosis prevention (CHR program), substance use prevention, stress management, improved adherence to maintenance medication; education on early warning signs of relapse.
13. ReferencesStrakowski SM. Schizophreniform disorder. In: Tasman A, Kay J, eds. Psychiatry. 2003 … and 9 other papers

1. History

The historical origin of acute schizophrenia-like psychotic disorder (F23.2) goes back to 1939, when the Norwegian psychiatrist Gabriel Langfeldt proposed the concept of 'schizophreniform psychosis.' Langfeldt used this term to distinguish the clinical characteristics of patients who met the clinical criteria for schizophrenia but had a markedly better prognosis and could recover completely. He proposed acute onset, good premorbid functioning, accompanying affective symptoms, and a confusional state as features of a good prognosis.

Until the mid-20th century, schizophreniform psychosis was not recognized as an independent diagnostic category and was regarded as a course or subtype of schizophrenia. In 1980, DSM-III first established 'schizophreniform disorder' as an independent, official diagnostic category, defined as symptoms lasting 2 weeks or more but less than 6 months. The criteria were subsequently refined through DSM-III-R and DSM-IV, and DSM-5 retained a duration of 1 month or more but less than 6 months and added the good prognostic features specifier.

In ICD-10 (1992) it is classified as F23.2 and describes an acute episode that meets schizophrenia criterion A but lasts less than 1 month. This differs from DSM-5 schizophreniform disorder (1-6 months) in the duration criterion, and the ICD-10 criteria require a stricter, shorter course. The 1-6 month duration of DSM-5 schizophreniform disorder is divided in ICD-10 into F23.2 (less than 1 month) and F20 (schizophrenia, 1 month or more). Such differences between the systems require caution when comparing epidemiology, treatment, and prognosis data for F23.2 and schizophreniform disorder. In ICD-11, the criteria for this category were partly adjusted.


2. Causes

The cause of F23.2 shares essentially the same neurobiological mechanisms as schizophrenia, and the possibility of short-term recovery is the main etiological characteristic that distinguishes it from schizophrenia.

Biological causes shared with schizophrenia: Mesolimbic dopamine hyperactivity and prefrontal dopamine D1 receptor hypoactivity cause the positive symptoms of F23.2, as in schizophrenia. Dysregulation of glutamate due to NMDA receptor hypofunction provides the neurobiological basis for hallucinations, delusions, and disorganization symptoms. Abnormal prefrontal-limbic connectivity impairs reality testing.

Basis for the possibility of short-term recovery: The following are proposed as reasons why F23.2, unlike schizophrenia, shows the possibility of short-term recovery: ① the severity of the underlying neurobiological abnormality is lower than in schizophrenia; ② neuroplasticity is still sufficiently preserved; ③ normalization of dopamine hyperactivity as the precipitating stress resolves is more common than in schizophrenia; ④ negative symptoms and cognitive deficits are milder than in schizophrenia, so complete recovery is often possible.

Role of acute stress: Acute psychosocial stress is often identified before the onset of F23.2. A mechanism is proposed in which a surge of cortisol due to HPA axis hyperactivity temporarily destabilizes the dopamine system, causing symptoms that meet schizophrenia criteria, followed by recovery as the stress resolves.

Substance use: Substances such as cannabis, amphetamines, cocaine, and synthetic cannabinoids (K2, Spice) can cause acute psychotic episodes that are difficult to distinguish from symptoms meeting schizophrenia criteria. Substance-induced psychosis must be thoroughly excluded, and if symptoms resolve rapidly after substance use is discontinued, it is diagnosed as substance-induced psychosis rather than F23.2.


3. Genetics

F23.2 (schizophreniform disorder) shows high genetic overlap with schizophrenia, and some cases are in fact the initial episode of schizophrenia.

Family studies: The risk of schizophrenia is significantly higher in first-degree relatives of patients with schizophreniform disorder than in the general population. Conversely, schizophreniform disorder also occurs more frequently in relatives of patients with schizophrenia. This suggests that the two disorders have a strong genetic association and supports that part of F23.2 belongs to the genetic spectrum of schizophrenia.

Polygenic risk score: In large studies, the schizophrenia polygenic risk score (PRS) is also elevated in patients with schizophreniform disorder, and the PRS level is positively correlated with the subsequent risk of conversion to schizophrenia. More intensive follow-up and treatment are recommended for patients with a high PRS.

GWAS data: Variants at 108 or more loci identified in schizophrenia GWAS may also be associated with schizophreniform disorder, but there is not yet an F23.2-specific GWAS. Schizophrenia risk genes (DISC1, NRG1, DTNBP1, C4A, 22q11.2 deletion, etc.) are presumed to contribute to vulnerability to F23.2 onset as well.

Clinical application: For F23.2 patients with a family history of schizophrenia (first-degree relatives), the conversion risk is high, so longer-term maintenance antipsychotic treatment and intensive follow-up are planned. Genetic counseling is provided as needed, giving realistic and balanced information about the possibility of conversion.


4. General epidemiology

The epidemiology of F23.2 is mainly referenced from studies of schizophreniform disorder in the DSM system, and differences between the ICD criteria and the duration definition must be taken into account.

Incidence: In the DSM system, the annual incidence of schizophreniform disorder is estimated at about 1-2 per 100,000 population, about 1/10 that of schizophrenia. The incidence of ICD-10 F23.2 is estimated to be lower than that of DSM schizophreniform disorder because of its stricter duration criterion of less than 1 month.

Sex and age: As in schizophrenia, onset is slightly earlier in men (early 20s) and somewhat later in women (late 20s to early 30s). Overall, onset is concentrated in early adulthood (ages 18-35).

Conversion to schizophrenia: About 30-50% of patients with schizophreniform disorder are diagnostically converted to schizophrenia on long-term follow-up. This high conversion rate is the clinical basis for understanding F23.2 not as a simple transient psychosis but as a prodrome or initial episode of schizophrenia. Flat affect, lack of insight, poor premorbid functioning, and a family history of schizophrenia are reported as predictors of conversion.

Status in Korea: Independent epidemiologic data on F23.2 are limited in Korea, but National Health Insurance claims data show that the F23 group as a whole accounts for tens of thousands of visits per year. The Early Psychosis Intervention (EPI) program is operated nationwide through mental health welfare centers.


5. Pathophysiology

The pathophysiology of F23.2 follows the same neurobiological model as schizophrenia, with additional consideration of factors that explain the possibility of short-term recovery.

Dopamine hypothesis: Mesolimbic dopamine D2 receptor hypersensitivity is central to the development of the positive symptoms of F23.2 (hallucinations, delusions, disorganization). Aberrant salience due to dopamine hyperactivity causes delusion formation and hallucinatory experiences. PET studies have reported that striatal dopamine synthesis capacity is increased in patients with an acute schizophreniform episode, similar to schizophrenia.

Glutamate-NMDA hypothesis: Reduced function of inhibitory interneurons due to NMDA receptor hypofunction causes excessive cortical excitability and induces hallucinations and delusions. Encephalitis due to autoimmune NMDA receptor antibodies (anti-NMDAR) causes acute psychotic symptoms similar to F23.2, so differentiation is important.

Mechanism of the possibility of short-term recovery: The prefrontal gray matter reduction, abnormal synaptic pruning, and hippocampal neuronal loss observed in chronic schizophrenia may not yet be entrenched or may be mild in F23.2. Rapid suppression of dopamine hyperactivity by early treatment (antipsychotics) minimizes neural damage and enables recovery. This is why minimizing the DUP (duration of untreated psychosis) is decisive for prognosis.


6. Symptoms

The core symptoms of F23.2 are psychotic symptoms that meet schizophrenia diagnostic criterion A and last less than 1 month by ICD-10 criteria, or within 1-6 months by DSM-5 schizophreniform disorder criteria.

Positive symptoms: Hallucinations appear (mainly auditory: persistent voices, voices conversing with each other, voices commenting on behavior). Delusions appear (mainly persecutory or grandiose), with a degree of systematization that varies, as in schizophrenia. Disorganized speech (derailment, incoherence, word salad) may appear. Disorganized or catatonic behavior may also be observed.

Negative symptoms: Avolition, alogia, and affective flattening may appear but are often milder than in schizophrenia. Relatively better premorbid functioning than in schizophrenia is one of the good prognostic features in DSM-5.

Duration criterion: Less than 1 month in ICD-10 F23.2; 1-6 months in DSM-5 schizophreniform disorder. If symptoms exceed 1 month by ICD-10 criteria or 6 months by DSM-5 criteria, they are reclassified as F20 (schizophrenia) or schizophrenia, respectively. F23.2 is therefore strongly a provisional diagnosis in terms of time.

DSM-5 good prognostic features: ① prominent confusion or perplexity; ② good premorbid social and occupational functioning; ③ absence of oddness in thinking, perception, and speech identified in psychotic-level symptoms within 4 weeks of episode onset; ④ no flat affect after onset — the good prognostic features specifier is noted when 2 or more of these are met.


7. Signs

The clinical signs of F23.2 are very similar to those of a first episode of schizophrenia, and it is difficult to distinguish clinically from schizophrenia until the temporal course is established.

Mental status examination findings: Positive symptoms are prominent. In speech, tangentiality, loose associations, and neologisms may appear. Delusional thought content is detailed and specific. Behavior based on auditory hallucinations (responding to voices or muttering) may be observed. Affect may be flat or inappropriate. Cognitive function may be impaired in the acute phase but can return to baseline after recovery.

Assessment of negative symptoms: Even when negative symptoms are present in F23.2, they are often milder and transient compared with schizophrenia. Marked and persistent negative symptoms suggest the possibility of schizophrenia. The severity of negative symptoms is quantified using the PANSS negative symptom subscale (N1-N7).

Neuropsychological test findings: Neurocognitive deficits similar to schizophrenia (decreased attention, working memory, and processing speed) may appear in the acute phase. However, cognitive function returning to baseline after full recovery is more common than in schizophrenia. Whether cognitive function recovers is an important indicator in assessing long-term prognosis and conversion risk.


8. Screening

F23.2 is a core target of early psychosis services and requires immediate, comprehensive evaluation.

Early psychosis assessment: Assessment of the early psychosis clinical high-risk state with CAARMS (Comprehensive Assessment of At-Risk Mental States) or SIPS/SOPS; quantification of symptom severity with PANSS or BPRS; assessment of functional level with CGI (Clinical Global Impression scale); tracking of functional level with GAF (Global Assessment of Functioning scale) are required.

Complete exclusion of organic causes: An autoimmune encephalitis panel (anti-NMDAR, anti-LGI1, anti-CASPR2, anti-AMPAR, anti-GABA-B antibodies, etc.) must be considered in a young adult's first acute psychotic episode. Anti-NMDAR encephalitis often presents with seizures, autonomic instability, and movement abnormalities along with acute psychotic symptoms, so differentiation is important. Brain MRI (including DWI and FLAIR), EEG, and cerebrospinal fluid examination are performed when necessary.

Minimizing DUP: It has been confirmed in both schizophrenia and schizophreniform disorder that the longer the duration of untreated psychosis (DUP), the worse the prognosis. Therefore, starting antipsychotic treatment as soon as possible after the onset of acute psychotic symptoms is the key to minimizing DUP and improving prognosis.


9. Diagnosis

The diagnosis of F23.2 centers on confirming that schizophrenia criteria are met and verifying the duration, and thorough exclusion of organic causes is essential.

ICD-10 F23.2 diagnostic criteria: ① At least 1 of the ICD-10 F20 schizophrenia criteria G1 is met (or at least 2 from each of groups G1.2-G1.4); ② the whole episode lasts less than 1 month; ③ organic causes are excluded; ④ mood disorder criteria are not met (any accompanying mood episode is brief and secondary).

DSM-5 schizophreniform disorder criteria: ① Schizophrenia criterion A (2 or more of hallucinations, delusions, disorganized speech, disorganized behavior/catatonia, negative symptoms; at least 1 must be hallucinations, delusions, or disorganized speech); ② episode duration of 1 month or more but less than 6 months; ③ exclusion of schizoaffective disorder, mood disorders, and substance or medical causes. The good prognostic features specifier may be noted.

Temporal reclassification: If criterion A symptoms of schizophrenia persist for 1 month (ICD) or 6 months (DSM) or more, they are reclassified as F20 or schizophrenia, respectively. It is important to record the symptom duration accurately through weekly or biweekly follow-up assessments.

Differential diagnosis: The main differential diagnoses are schizophrenia (differentiated by duration), F23.0/F23.1 (differentiated by polymorphic features and first-rank symptoms), schizoaffective disorder (accompanied by mood episodes), substance-induced psychosis, autoimmune encephalitis (accompanied by fever, seizures, and autonomic abnormalities), and psychosis accompanying a manic episode of bipolar disorder.


10. Treatment

Treatment of F23.2 follows the principles of early psychosis treatment, and sufficient maintenance treatment considering the risk of conversion to schizophrenia is recommended.

Antipsychotics: Atypical antipsychotics (risperidone, olanzapine, aripiprazole, quetiapine) are the first choice. In early psychosis, start at the minimum effective dose and adjust according to response. Starting treatment as early as possible is recommended to shorten the DUP. Maintenance treatment for at least 12-24 months after remission of the acute phase is recommended, and longer maintenance is considered when the risk of conversion to schizophrenia is high.

Intensive early psychosis program: F23.2 patients are linked to an intensive early psychosis program (EPI, NAVIGATE, etc.). These programs provide comprehensive services integrating medication, individual psychotherapy, family education, and supported employment/education, and have been shown in large RCTs (such as the RAISE study) to be effective in improving long-term prognosis.

Cognitive behavioral therapy: CBTp helps reduce residual positive symptoms, relapse risk, and psychosis-related distress. It includes normalization of psychosis, recognition of early warning signs, and strengthening of coping strategies. Family education aims to reduce high expressed emotion (EE) and strengthen family support.


11. Prognosis

The prognosis of F23.2 is good in the short term, but the risk of conversion to schizophrenia makes the long-term prognosis uncertain.

Short-term prognosis: With active treatment, a marked reduction in acute symptoms within weeks to months is possible in most patients. The complete remission rate varies by study, but recovery to the baseline level of functioning is reported in about 60-80% of those who receive appropriate treatment.

Long-term prognosis and conversion to schizophrenia: On long-term follow-up (5-10 years), about 30-50% convert to schizophrenia. This conversion rate is markedly higher than for F23.0 (10-15%) and F23.1 (20-30%). In the remaining 50-70%, even with recurrent episodes, the disorder does not develop into chronic schizophrenia, or complete remission is maintained. Conversion to bipolar disorder is also reported in some patients.

Effect of DUP on prognosis: There is consistent evidence that the shorter the DUP (less than 6 months, especially less than 3 months), the higher the remission rate and the better the long-term functional prognosis. This is the key rationale for early psychosis services' efforts to minimize DUP.


12. Prevention

Prevention of F23.2 takes place at three levels: early psychosis prevention, suppression of conversion to schizophrenia, and relapse prevention.

Early intervention in clinical high-risk groups: Early intervention for individuals in the clinical high-risk (CHR) state—attenuated psychotic symptoms, brief self-limiting psychotic symptoms, or a combination of genetic risk and functional decline—contributes to preventing conversion to F23.2. Evidence is accumulating that low-dose antipsychotics, CBT, and omega-3 fatty acid supplementation are effective in preventing conversion in the CHR state. Korea's early psychosis prevention program (based at mental health welfare centers) fulfills this role.

Substance use prevention: Cannabis (especially high-concentration THC) and other psychostimulants bring forward the onset of schizophrenia spectrum disorders in individuals with genetic vulnerability. Substance use prevention education for adolescents is important.

Prevention of conversion to schizophrenia: Improving adherence to maintenance medication (medication education, consideration of LAI), education on early warning signs of relapse, and regular follow-up contribute to preventing or delaying conversion to schizophrenia.


13. References

  1. Strakowski SM. Schizophreniform disorder. In: Tasman A, Kay J, eds. Psychiatry. 2003. (Clinical review of schizophreniform disorder.)

  2. Lieberman JA, Fenton WS. Delayed detection of psychosis: causes, consequences, and effect on public health. American Journal of Psychiatry. 2000;157(11):1727-1730. DOI: 10.1176/appi.ajp.157.11.1727. PMID: 11058468.

  3. Pillmann F, Marneros A. Brief and acute psychoses: the development of concepts. History of Psychiatry. 2005;16(64 Pt 4):385-403. DOI: 10.1177/0957154X05052952. PMID: 16475266.

  4. Kane JM, Robinson DG, Schooler NR, et al. Comprehensive versus usual community care for first-episode psychosis: 2-year outcomes from the NIMH RAISE early treatment program. American Journal of Psychiatry. 2016;173(4):362-372. DOI: 10.1176/appi.ajp.2015.15050632. PMID: 26481174.

  5. Castagnini A, Berrios GE. Acute and transient psychotic disorders (ICD-10 F23): a review from a European perspective. European Archives of Psychiatry and Clinical Neuroscience. 2009;259(8):433-443. DOI: 10.1007/s00406-009-0008-3. PMID: 19247624.

  6. McGorry PD, Yung AR, Phillips LJ, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry. 2002;59(10):921-928. DOI: 10.1001/archpsyc.59.10.921. PMID: 12365879.

  7. Marneros A, Pillmann F. Acute and transient psychoses. Cambridge University Press. 2004. ISBN: 9780521529952.

  8. Jorgensen P, Bennedsen B, Christensen J, Hyllested A. Acute and transient psychotic disorder: a 1-year follow-up study. Acta Psychiatrica Scandinavica. 1997;96(2):99-104. DOI: 10.1111/j.1600-0447.1997.tb09910.x. PMID: 9272193.

  9. Correll CU, Galling B, Pawar A, et al. Comparison of early intervention services vs treatment as usual for early-phase psychosis. JAMA Psychiatry. 2018;75(6):555-565. DOI: 10.1001/jamapsychiatry.2018.0623. PMID: 29800939.

  10. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: WHO; 1992. (See for F23.2 classification criteria.)